Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

Nobel Prize-winner presents first lecture at Vice-Chancellor’s prestige lecture series
2017-11-17


 Description: Prof Levitt visit Tags: Prof Levitt visit

At the first lecture in the UFS Vice Chancellor’s Prestige Lecture series,
were from the left: Prof Jeanette Conradie, UFS Department of Chemistry;
Prof Michael Levitt, Nobel Prize-winner in Chemistry, biophysicist and
professor in structural biology at Stanford University; Prof Francis Petersen,
UFS Vice-Chancellor and Rector; and Prof Corli Witthuhn,
UFS Vice-Rector: Research. 
Photo: Johan Roux

South African born biophysicist and Nobel Prize-winner in Chemistry, Prof Michael Levitt, paid a visit to the University of the Free Sate (UFS) as part of the Academy of Science of South Africa’s (ASSAf) Distinguished Visiting Scholars’ Programme. 

Early this week the professor in structural biology at Stanford University in the US presented a captivating lecture on the Bloemfontein Campus on his lifetime’s work that earned him the Nobel Prize in 2013. His lecture launched the UFS Vice-Chancellor’s Prestige Lecture series, aimed at knowledge sharing within, and beyond our university boundaries. 

Prof Levitt was one of the first researchers to conduct molecular dynamics simulations of DNA and proteins and developed the first software for this purpose. He received the prize for Chemistry, together with Martin Karplus and Arieh Warshel, “for the development of multiscale models for complex chemical systems”.

Attending the lecture were members of UFS management, academic staff from a range of faculties and other universities as well as young researchers. “Multiscale modelling is very much based on something that makes common sense,” Prof Levitt explained. “And that is to makes things as simple as possible, but not simpler. Everything needs to have the right level of simplicity, that is not too simple, but not too complicated.”  

An incredible mind
Prof Levitt enrolled for applied mathematics at the University of Pretoria at the age of 15. He visited his uncle and aunt in London after his first-year exams, and decided to stay on because they had a television, he claims. A series on molecular biology broadcast on BBC, sparked an interest that would lead Prof Levitt via Israel, and Cambridge, to the Nobel Prize stage – all of which turned out to be vital building blocks for his research career. 

Technology to the rescue
The first small protein model that Prof Levitt built was the size of a room. But that exercise led to the birth of multiscale modelling of macromolecules. For the man on the street, that translates to computerised models used to simulate protein action, and reaction. With some adaptations, the effect of medication can be simulated on human protein in a virtual world. 

“I was lucky to stand on the shoulder of giants,” he says about his accomplishments, and urges the young to be good and kind. “Be passionate about what you do, be persistent, and be original,” he advised.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept